Trump Executive Order: Social media erupted with optimism after President Trump's executive order slashed psychedelic drug approval timelines from months to weeks, propelling ATAI shares higher. Investors praised the company's lead candidate BPL-003 nasal spray for depression, positioning it at the forefront of accelerated regulatory pathways. Many see this policy shift as unlocking multibillion-dollar opportunities in mental health treatments.
Guggenheim Upgrade: Chatter amplified following Guggenheim's price target hike to $16 from $11 with a Buy rating, highlighting BPL-003's Phase III start this quarter and cash runway to 2029. Participants underscored the short-acting psychedelic's edge in patient preference and clinic scalability. The upgrade reinforced views of ATAI as a paradigm shifter in treatment-resistant depression.
Pipeline Depth: Beyond BPL-003, discussions spotlighted ATAI's robust lineup including VLS-01 and ibogaine analogs for PTSD and addiction. Strong balance sheet and recent Beckley acquisition drew acclaim for de-risking execution. Sentiment portrays ATAI as uniquely primed for the psychedelic renaissance.
Note: This discussion summary was generated from an AI condensation of post data.
ATAI Life Sciences Insider Trading Activity
ATAI Life Sciences insiders have traded $ATAI stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ATAI stock by insiders over the last 6 months:
- KEVIN JAMES CRAIG (Chief Medical Officer) sold 100,000 shares for an estimated $355,000
- COSMO FEILDING-MELLEN sold 39,594 shares for an estimated $154,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ATAI Life Sciences Hedge Fund Activity
We have seen 72 institutional investors add shares of ATAI Life Sciences stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 7,677,289 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,400,112
- DEEP TRACK CAPITAL, LP added 4,677,289 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,130,112
- BLACKROCK, INC. added 2,808,808 shares (+63836.5%) to their portfolio in Q4 2025, for an estimated $11,488,024
- FORESITE CAPITAL MANAGEMENT VI LLC added 2,750,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,247,500
- RTW INVESTMENTS, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,180,000
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,936,267 shares (-99.8%) from their portfolio in Q4 2025, for an estimated $7,919,332
- AMERIPRISE FINANCIAL INC added 1,735,252 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,097,180
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ATAI Life Sciences Analyst Ratings
Wall Street analysts have issued reports on $ATAI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/20/2026
To track analyst ratings and price targets for ATAI Life Sciences, check out Quiver Quantitative's $ATAI forecast page.
ATAI Life Sciences Price Targets
Multiple analysts have issued price targets for $ATAI recently. We have seen 6 analysts offer price targets for $ATAI in the last 6 months, with a median target of $15.5.
Here are some recent targets:
- Sumant Kulkarni from Canaccord Genuity set a target price of $15.0 on 04/20/2026
- Eddie Hickman from Guggenheim set a target price of $16.0 on 04/17/2026
- David Hoang from Deutsche Bank set a target price of $12.0 on 03/27/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $25.0 on 03/17/2026
- Ami Fadia from Needham set a target price of $14.0 on 03/09/2026
- Justin Walsh from Jones Trading set a target price of $16.0 on 12/23/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
